Revenue Performance - For the year ended August 31, 2020, the company reported revenue of $384,543, an increase of $161,933 compared to $222,610 in 2019[318]. - Licensing revenue accounted for $232,909 of total revenue, up from $198,000 in 2019, while product and other revenues increased to $151,634 from $24,610[320]. - Total revenue for the year ended August 31, 2019 was $222,610, down from $433,287 in 2018, reflecting a decrease of 48.6%[329]. - Licensing revenues accounted for $198,000 of total revenues, primarily due to delays in usage fee revenues from existing licensees in Canada[330]. - The company anticipates continued revenue generation from technology licensing, with expectations for increased usage fees as licensees ramp up production[336]. Net Loss and Financial Position - The net loss for the year was $4,084,613, a slight improvement from the net loss of $4,158,413 in 2019, reflecting a change of $73,800[318]. - The company reported a net loss attributable to common shareholders of $3,933,996 for the year ended August 31, 2020, a slight improvement from the previous year's loss of $4,099,420[348]. - For the year ended August 31, 2019, the company reported a net loss of $4,158,413, a decrease of 37% compared to a net loss of $6,609,186 in 2018[329]. Working Capital and Cash Position - The company had a working capital surplus of $1,700,044 as of August 31, 2020, compared to $1,634,322 in 2019, indicating a positive working capital position[324]. - The company had a working capital balance of $1,634,322 as of August 31, 2019, a decrease from $2,240,411 in 2018[342]. - The company maintained a cash position of $1,293,749 as of August 31, 2020, with an estimated requirement of $2.0 million to finance planned expenditures for the upcoming year[297]. Operating Activities and Expenses - Cash flows used in operating activities decreased to $2,663,281 in 2020 from $3,005,555 in 2019, primarily due to reduced costs in advertising and R&D[326]. - Net cash used in operating activities was $3,005,555 for the year ended August 31, 2019, compared to $2,517,979 in 2018, indicating an increase of 19.3%[344]. - General and administrative expenses decreased by $2,659,158 to $4,358,130 in 2019, largely due to reduced non-cash expenses[338]. Future Plans and Funding - Estimated funding required for the next 12 months is approximately $3,305,000, with significant allocations for consulting fees ($1,200,000) and R&D ($650,000)[296]. - The company plans to focus on technology licensing in the nicotine and pharmaceutical sectors, with an emphasis on expanding R&D for DehydraTECH applications[297]. - The company plans to conduct additional studies to test the absorption of various molecules, which could enhance the acceptance of DehydraTECH technology[315]. - The company has six revenue-generating agreements with licensees and is pursuing additional licensing opportunities in the cannabinoids and nicotine markets[313]. - The company expanded its number of licensees from 1 to 9 over the two-year period ending August 31, 2019, indicating significant growth in licensing agreements[331]. Financing Activities - Cash flows from financing activities increased to $3,332,683 in 2019, compared to $1,867,224 in 2018, reflecting a growth of 78.3%[346].

Financial Performance - Revenue for the nine months ended May 31, 2020, was $250,804, an increase of $153,315 compared to $97,489 in the same period of 2019[121]. - Product revenues of $119,691 represented almost half of total revenues during the period, primarily from intermediate product sales[122]. - Licensing revenue was $130,509, reflecting delays due to product approval processes and the impact of the COVID-19 pandemic[123]. - The company's net loss for the nine months ended May 31, 2020, was $3,312,908, compared to a net loss of $3,042,438 in the same period of 2019[121]. - Cash flows used in operating activities were $1,981,314 for the period, an improvement from $2,268,946 in the same period of 2019[133]. Research and Development - The company commenced research on the benefits of its DehydraTECH Technology for enhancing the delivery of certain antiviral drugs[96]. - A new US patent application was filed for "Compositions and Methods for Enhanced Delivery of Antiviral Agents" to combat infectious diseases including COVID-19[97]. - A pilot human pharmacokinetic exploratory study is planned to compare DehydraTECH formulations to controls without the technology[104]. - The company incurred $318,830 in research and development expenditures for the period ending May 31, 2020, down from $394,091 in 2019[110]. COVID-19 Impact - The COVID-19 pandemic has presented significant risks, potentially leading to lower revenues and higher losses[100]. - The company continues to monitor governmental programs related to the COVID-19 pandemic[105]. - The COVID-19 pandemic has not materially impacted internal controls, aside from increased remote working requirements[147]. Financial Position - Current assets increased to $2,528,111 as of May 31, 2020, compared to $1,818,829 in 2019, resulting in a net working capital of $2,408,383[131]. - The company had $2,034,011 in cash and cash equivalents as of May 31, 2020, sufficient to continue operations for at least the next seven months[138]. - The company maintained a positive working capital position throughout the period, supported by private placements and option exercises[131]. Operational Changes - The company amended its license agreement with Universal Hemp LLC, reducing minimum performance fees from $3,750,000 to $132,500[95]. - The company terminated a license for THC-based beverages originally announced on April 24, 2019[99]. - Cost containment initiatives were implemented, including the dismissal of one employee and termination of contracts with two consultants[101]. - The company has not experienced significant impacts on material supply chains but noted increased timelines from some research facilities[102]. Internal Controls - Management assessed the effectiveness of internal control over financial reporting as of May 31, 2020, concluding it is effective in providing reasonable assurance regarding reliability of financial reporting[144]. - No changes in internal controls over financial reporting occurred during the quarter ended May 31, 2020, that materially affect the controls[146]. - There are no material, existing or pending legal proceedings against the company[148].

¨ RANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE CORP. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2020 or (Address of principal executive offices) (Zip Code) Regist ...

Revenue and Growth - For the period ended November 30, 2019, the company reported total revenue of $62,082, an increase of 179.5% compared to $22,209 for the same period in 2018[93]. - Licensing revenues accounted for $51,750 of total revenues, reflecting delays in usage fee revenues from existing licensees awaiting product approval from Health Canada[94]. - The company expects increases in revenues during the 2020 calendar year as licensees ramp up production[95]. Expenses and Losses - General and administrative expenses increased by $223,372 to $978,992, primarily due to non-cash expenses related to share-based payments[97]. - The net loss for the period was $924,763, compared to a net loss of $701,391 in the previous year, indicating increased operational costs[93]. - Consulting fees increased by $242,991, primarily due to non-cash share-based payments of $233,166[99]. - Net cash used in operating activities was $762,845, compared to $564,314 in the same period of 2018, reflecting increased consulting and staff wage costs[102]. - The company expects to continue incurring losses in the short term due to ongoing research and development expenditures[105]. Research and Development - Research and development expenditures for the period were $107,463, up from $96,973 in 2018, indicating ongoing investment in R&D[82]. - The company plans to conduct in vivo absorption tests on CBD, which have yielded positive results in preliminary testing[83]. - Significant funding will be required to achieve objectives for developing and patenting intellectual property, potentially amounting to millions of dollars[108]. Financial Position - The company has no debt other than month-to-month receivables, indicating a strong liquidity position[98]. - Current assets as of November 30, 2019, were $1,911,485, up from $1,818,829 on August 31, 2019[100]. - Net working capital increased to $1,781,256 from $1,634,322, indicating a positive working capital position[100]. - As of November 30, 2019, the company had $1.3 million in cash and cash equivalents, sufficient for at least the next six months[107]. Capital Raising and Funding - The company closed a private placement of 1,823,745 units at $0.45 each, raising capital for future operations[78]. - Net cash provided from financing activities was $706,704, down from $1,649,190 in the same period of 2018[104]. - The company will evaluate various funding alternatives to maintain operations and expand its patent portfolio, with no assurance of favorable terms for additional funding[106]. Intellectual Property - The company has over 50 patent applications pending worldwide, demonstrating a strong focus on intellectual property protection[71].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) | Nevada | 20-2000871 | | --- | --- | | State or other ju ...

Financial Performance - The company reported a net loss of $3,042,438 for the nine-month period ended May 31, 2019, compared to a net loss of $5,382,003 in the same period of 2018, reflecting an improvement of $2,339,565[253]. - Revenue for the nine-month period was $97,489, down from $336,933 in the previous year, indicating a decrease of $239,444[253]. - General and administrative expenses decreased to $3,131,983 from $5,684,088, a reduction of $2,552,105, primarily due to lower consulting expenses[255]. - For the three-month period ended May 31, 2019, the company reported a net loss of $1,187,936, an improvement from a net loss of $3,424,912 in the same period of 2018, showing a reduction of $2,236,976[257]. - Sales for the three-month period were $59,931, down from $140,340 in the previous year, a decrease of $80,409[257]. - The company incurred $394,091 in research and development expenditures during the period ending May 31, 2019, compared to $279,221 in 2018[234]. - The company's working capital increased to $2,475,306 as of May 31, 2019, due to a private placement and the exercise of options and warrants[263]. - Cash flows used in operating activities increased to $(2,268,946) for the nine months ended May 31, 2019, primarily due to higher legal expenses and employee hiring[264]. - The company raised a total of $2,318,812 from equity issuances during the period ended May 31, 2019[267]. Intellectual Property and Technology - The company has been granted a total of 11 patents within its first patent family, significantly strengthening its intellectual property claims in the US and Australia[106]. - The company has over 50 patent applications pending worldwide, reflecting its aggressive pursuit of patent protection for its DehydraTECH technology[97]. - The company aims to develop strategic partnerships with licensees for its patented technology, focusing on both up-front and staged licensing fees[101]. - Lexaria is focusing on expanding its portfolio of patent pending applications and technology licensing opportunities in the food and supplement sectors[130]. - Lexaria's patented DehydraTECH technology has shown a 499% increase in CBD permeability compared to baseline levels, indicating significant improvements in bioavailability[165]. - The company has filed for international patent protection under the Patent Cooperation Treaty, covering 148 countries[149]. - Lexaria has received multiple patents for its DehydraTECH technology, with the first patent granted in October 2016[148]. - The company has entered more than 10 formal letters of intent or definitive agreements and is negotiating more to strengthen its intellectual property portfolio[262]. Product Development and Launches - The company launched ChrgD+, a water-soluble, ready-mix hemp supplement powder, in collaboration with Cultivating Wellness Inc., targeting a wide distribution network[111]. - Lexaria has launched a line of premium hemp oil products, targeting a customer base that is expected to grow, with only 1% of the American population currently consuming hemp food products[143]. - Lexaria's TurboCBD™ demonstrated a total area under the curve (AUC) of 10,865 ± 6,322 for CBD levels in the bloodstream, compared to 7,115 ± 2,978 for the positive control formulation[118]. - Lexaria's TurboCBD™ capsules delivered 317% more CBD to blood at the 30-minute mark compared to the positive control formulation, with levels of 18.4 ng/mL versus 4.4 ng/mL[178]. - The initial release of the TurboCBD product was successful, although sales were limited by external payment processing changes[259]. Research and Development - The company is working on cannabinoid-related formulations and other bioactive compounds in its new R&D laboratory in Kelowna, expected to reduce costs and development timelines[112]. - The company plans to increase personnel over the next 12 months to enhance capacity for R&D, subject to regulatory approval[233]. - The company continues to explore new R&D programs to enhance its technology and expand product applications[236]. - Lexaria's technology could potentially enhance the absorption of fat-soluble vitamins, leading to lower dosages required compared to current pill forms[162]. Market and Industry Insights - The Organic Food sector in the USA was valued at $246 billion in 2014, while the Dietary Supplements market was worth $34.6 billion[144]. - The global pain management market was estimated at $22 billion in 2011, with NSAIDs accounting for $5.4 billion of that market[156]. - The global vitamin and supplement market is valued at $68 billion, with the U.S. being the largest single national market[160]. - The legal marijuana industry in the USA generated over $8 billion in revenue in 2016, with projections of $20 billion or more by 2020[218]. - The trend of consumer acceptance for hemp oil fortified foods and hemp seed products is expected to support higher potential sales in the future[259]. - The 2018 Farm Bill may positively impact the industry by lifting restrictions on advertising, marketing, and interstate commerce for hemp and CBD[226]. Strategic Partnerships and Agreements - The company has established four wholly-owned subsidiary companies to better reflect distinct customer bases and business applications[109]. - The company has a joint venture agreement with Enertopia Corp for a prospective medical marijuana business, holding a 49% net ownership interest[93]. - Altria Ventures Inc. will initially fund Lexaria Nicotine LLC with $1 million, with the potential for up to $12 million in additional funding through phased private financings[116]. - Lexaria entered a 10-year renewal licensing agreement with Nuka Enterprises, allowing semi-exclusive use of DehydraTECH technology across the US, with options to expand to Canada[205]. - A comprehensive agreement with Nuka Enterprises LLC allows for expansion into multiple states, utilizing DehydraTECH technology for CBD products until 2028[125]. - The company executed a contract with M&E Services Ltd. for consulting services at CAD$12,000 per month, with an 8% annual increase[230]. Operational Developments - The company has established a new head-office location in Kelowna, Canada, and is constructing a federally licensed laboratory for internal R&D purposes[227]. - The company is in the process of finalizing the online ordering portal for retail and channel distribution, expected to be operational in Q4 of fiscal 2019[259]. - Lexaria plans to hire three to six employees and has already hired three, with a fourth expected to join during the fiscal fourth quarter[216].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2019 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ____________ Commission File Number _____________________ Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2018 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ Commission File Number _______________ Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) (State or other jur ...